Quick Details
|
Product Name |
Terlipressin |
|
CAS |
14636-12-5 |
|
EINECS |
238-680-8 |
|
Molecular Formula |
C52H74N16O15S2 |
|
Molecular Weight |
1227.37 |
|
Appearance |
White powder |
|
Application |
Vasoactive drugs manage low blood pressure |
|
Purity |
99% |
|
|
Dry low temperature -20 -80 degrees |
Description
The main active metabolite is lysine - vasopressin. Therefore, telopressin takes effect slowly, but its effect lasts a long time. Lysine - vasopressin is further degraded in liver, kidney other tissues.
After intravenous administration, the pharmacokinetic model of TRP in vivo is two-compartment model, with a half-life of about 40 minutes, a metabolic clearance rate of about 9 ml/kg/min, a distribution volume of about 0.5 l/kg. Lysine - vasopressin can be detected in vivo 30 minutes after administration peak within 60-120 minutes after administration.
indications
This product is used fthe treatment of bleeding in the gastrointestinal urogenital systems, such as esophageal varicose veins, gastric duodenal ulcers, uterine bleeding, production/miscarriage caused by functional other causes.
Fthe treatment of postoperative hemorrhage, especially in the peritoneal pelvic areas;
Local application of gynecological surgery, as in the cervix of the uterus.
Matters needing attention
The patient's blood pressure, heart rate fluid balance should be closely observed in the clinical application of this product, especially in the high dose range of 0.8 mg above.
Patients with hypertension, cardiac insufficiency the elderly need to pay close attention.
This product cannot be used as a blood substitute in patients with insufficient blood volume.
There have been reports of cases of necrosis of the administration site in the treatment with TRP. Therefore, it is recommended not to use muscle injection when the dosage is more than 0.5 mg.
